Apoptotic β-cells induce macrophage reprogramming under diabetic conditions.
Meliza G WardGe LiMingming HaoPublished in: The Journal of biological chemistry (2018)
Type 2 diabetes mellitus (T2DM) occurs when insulin-producing pancreatic β-cells fail to secrete sufficient insulin to compensate for insulin resistance. As T2DM progresses, apoptotic β-cells need to be removed by macrophages through efferocytosis that is anti-inflammatory by nature. Paradoxically, infiltrating macrophages are a main source of inflammatory cytokines that leads to T2DM. It is unclear how apoptotic β-cells impact macrophage function. We show under diabetic conditions, phagocytosis of apoptotic β-cells causes lysosomal permeabilization and generates reactive oxygen species that lead to inflammasome activation and cytokine secretion in macrophages. Efferocytosis-induced lipid accumulation transforms islet macrophages into foam cell-like outside the context of atherosclerosis. Our study suggests that whereas macrophages normally play a protective anti-inflammatory role, the increasing demand of clearing apoptotic cells may trigger them to undergo proinflammatory reprogramming as T2DM progresses. This shift in the balance between opposing macrophage inflammatory responses could contribute to chronic inflammation involved in metabolic diseases. Our study highlights the importance of preserving macrophage lysosomal function as a therapeutic intervention for diabetes progression.
Keyphrases
- induced apoptosis
- cell cycle arrest
- cell death
- anti inflammatory
- type diabetes
- glycemic control
- insulin resistance
- adipose tissue
- oxidative stress
- randomized controlled trial
- cardiovascular disease
- signaling pathway
- endoplasmic reticulum stress
- cell proliferation
- stem cells
- metabolic syndrome
- single cell
- cell therapy
- drug induced